Biotechnology
Virotherapy
Immuno – Oncology
Combination Therapy
Rigvir Group has established a grant competition for publications on clinical studies of oncolytic virotherapy, observations or clinical cases. Along with the financial contribution, the grant applicant name will appear in the publication as a co-author.
Any doctor or researcher preparing the scientific publication can participate in the competition. The only exception are employees of Rigvir Group and related companies, who cannot participate in the competition. Each grant is given for one article after publishing the article.
The study is intended on using oncolytic virotherapy rather than using oncolytic virotherapy in combination with other cancer therapies, medication etc.
Grant applicants should inform on the publication topic and present the document draft before commencing the project and submitting it to the chosen journal.
Our effort is based on fundamental goal to block the cancer mortality rates. We are seeking like-minded partners interested in development of oncolytic virotherapy products.
Melanoma
Uveal Melanoma
Stomach Cancer
Colorectal Cancer
Pancreatic Cancer
Kidney Cancer
Uterine Cancer
Bladder Cancer
Lung Cancer
Prostate Cancer
Several Types of Sarcoma
Breast Cancer